[1] Attal N, Bouhassira D. Neuropathic pain:experimental advances and clinical applications[J]. Rev Neurol, 2004, 160(2):199-203.
[2] Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain[J]. Oncologist, 2010, 15(Suppl2):3-8.
[3] Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain:involvement of inflammatory immune cells, immune-like glial cells and cytokines[J]. J Neuroimmunol, 2010, 229(1-2):26-50.
[4] Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes:mechanisms of action and place in therapy[J]. Drugs, 2000, 60(5):1029-1052.
[5] Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain[J]. Curr Pain Headache Rep, 2009, 13(3):185-190.
[6] Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics:a review[J]. J Clin Pharmacol, 2012, 52(1):6-17.
[7] Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline, in postherpetic neuralgia:a randomized, double-blind, crossover trial[J]. Pain, 1992, 48(1):29-36.
[8] Jefferies K. Treatment of neuropathic pain[J]. Semin Neurol, 2010, 30(4):425-432.
[9] Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision[J]. Eur J Neurol, 2010, 17(9):1113-1188.
[10] Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009, 25(7):623-631.
[11] Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain:systematic review of randomised trials[J]. BMC Neurol, 2008, 8:29.
[12] Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain:consensus statement and guidelines from the Canadian Pain Society[J]. Pain Res Manag, 2007, 12(1):13-21.
[13] Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel α-2-δ ligands:novel modulators of neurotransmission[J]. Trends Pharmacol Sci, 2007, 28(2):75-82.
[14] Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain:a randomized controlled trial from the Gabapentin Cancer Pain Study Group[J]. J Clin Oncol, 2004, 22(14):2909-2917.
[15] Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuopathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible-and fixed-dose regimens[J]. Pain, 2005, 115(3):254-263.
[16] Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain:A double-blind, randomized controlled crossover trial[J]. Lancet, 2009, 374(9697):1252-1261.
[17] Griggs RB, Bardo MT, Taylor BK. Gabapentin alleviates affective pain after traumatic nerve injury[J]. Neuroreport, 2015, 26(9):522-527.
[18] Câmara CC, Araújo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats[J]. Neurosci Lett, 2015, 607:52-58.
[19] Baillie JK, Power I. Morphine, gabapentin, or their combination for neuropathic pain[J]. N Engl J Med, 2005, 352(25):2650-2651.
[20] García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients results of oncology study[J]. Ann Oncol, 2011, 22(4):924-930.
[21] Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy:a randomized, double-blind, controlled, trial. Pain, 1999, 83(1):85-90.
[22] Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update[J]. Mayo Clin Proc,2010,85(3):S3-S14.
[23] Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy[J]. Pain, 2001, 91(1-2):101-109.
[24] Vadivelu N, Hines RL. Buprenorphine:a unique opioid with broad clinical applications[J]. J Opioid Manag, 2007, 3(1):49-58.
[25] Vadivelu N, Hines RL. Management of chronic pain in the elderly:focus on transdermal buprenorphine[J]. Clin Interv Aging, 2008, 3(3):421-430.
[26] Johnson RE, Fudala PJ, Payne R. Buprenorphine:considerations for pain management[J]. J Pain Symptom Manage, 2005, 29(3):297-326.
[27] Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain[J]. J Pain, 2009, 10(2):113-130.
[28] 神经病理性疼痛诊疗专家组. 神经病理性疼痛诊疗专家共识[J]. 中国疼痛医学杂志,2013,19(12):705-710.
[29] Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a change:optimizing communication and pain management decisions[J]. Curr Med Res Opin, 2011, 27(2):481-488.